Biotech Values

[stockbettor]

It does seem it will be difficult for the SPAC to raise enough additional cash to fund an RVNC buyout. I note that the S-1 has a dilution calculation showing that the cash paid by the IPO investors will suffer a roughly 96% reduction in value. Most of this results from omitting the IPO cash placed in trust. However, excluding the trust amount seems reasonable since it will not be accessible for at least 2 years if an acquisition does not occur within that period. An investment in the Saunders SPAC does not seem especially attractive at this point.